Insmed Catapults 30%, Leading A Biotech Rally; But Mirum Takes A Bath
Licensing
10:40 AM ET 08/06/2026
Insmed (INSM) stock led a biotech rally Thursday, catapulting nearly 30% on solid second-quarter sales for its new lung disease drug, Brinsupri. First, Brinsupri — a treatment for non-cystic fibrosis bronchiectasis — walloped sales expectations, generating $309.2 million vs. forecasts for $276.6 million, according to FactSet. Then, Insmed raised its guidance for the drug this year to $1.25 billion to…
